Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban.
Given the data for four factor prothrombin complex concentrate (PCC) for vitamin K antagonist (VKA) reversal, there is great interest to determine whether PCC can improve patient outcomes in patients with bleeds associated with the newer oral anticoagulants (NOAC). We describe the case of an adult trauma patient anticoagulated with apixaban, presenting with a severe life-threatening bleed. PCC was administered at the maximum dose when the patient was determined to be refractory to supportive care with blood products. Despite maximal treatment efforts, haemostasis was not achieved and the patient expired.